Bio-Path Holdings Earnings Call Transcripts
Fiscal Year 2025
-
DNAbilize technology enables high-dose, non-toxic delivery of antisense DNA drugs, with clinical progress in AML, solid tumors, and metabolic diseases. Key candidates show durable remissions and promising preclinical results, with several programs nearing IND filings and out-licensing opportunities.
Fiscal Year 2024
-
Expanded clinical pipeline into obesity and metabolic diseases while advancing multiple oncology programs. Q3 2024 net loss narrowed year-over-year, but cash reserves remain limited. Key data readouts and regulatory milestones are expected in early 2025.
-
Bio-Path Holdings presented robust clinical progress, including strong remission rates in AML trials and promising early results in solid tumors. The company highlighted its DNAbilize technology, expanding pipeline, strong IP, and financial position.
-
Second quarter saw improved financials, with net loss narrowing and cash position strengthened by new financing. Clinical programs advanced, highlighted by promising interim results for prexigebersen in AML and ongoing trials for BP1002, BP1001-A, and BP1003.